Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Rybrevant amivantamab Locally advanced or metastatic non-small cell lung cancer (NSCLC) Active
Rybrevant amivantamab Locally advanced or metastatic non-small cell lung cancer (NSCLC) Pending
Rydapt Midostaurin Acute Myeloid Leukemia Reimburse Complete
Rydapt Midostaurin Systemic Mastocytosis Do not reimburse Complete
Rylaze crisantaspase recombinant Acute lymphoblastic leukemia Reimburse with clinical criteria and/or conditions Complete
Samsca Tolvaptan Hyponatremia, non-hypovolemic Do not list Complete
Saphnelo anifrolumab Systemic lupus erythematosus Reimburse with clinical criteria and/or conditions Complete
Saphris Asenapine Schizophrenia Do not list Complete
Saphris Asenapine Bipolar I disorder List with clinical criteria and/or conditions Complete
Sarclisa isatuximab Multiple myeloma Reimburse with clinical criteria and/or conditions Complete